| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.9 | 3.1 |
| Gross profit | 1.0 | 1.9 |
| Net income | -3.2 | -1.1 |
| EPS (diluted, $ a share) | $-0.22 | $-0.21 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -37.5% |
|---|---|
| Gross margin | 54.2% |
| Operating margin | -28.1% |
10-Q filed with the SEC, OTC: CDIX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cardiff Lexington Corp: key numbers
- Share price
- $0.0050Close, Nov 17
- Market cap
- $110K
- Shares outstanding
- 22.05MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Offices & Clinics of Doctors of MedicineSIC 8011
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cardiff Lexington Corp
All →Cardiff Lexington Signs $104M M&A Deal with multi-location musculoskeletal healthcare platform
Cardiff Lexington Corporation has entered into a letter of intent to acquire a multi-location musculoskeletal healthcare platform for up to $104 million. The deal structure includes $30 million in cash, $10 million in notes, and preferred equity representing 35% of the company, plus $12 million in performance-based stock. The acquisition is intended to create a cornerstone regional healthcare platform and expand the company's orthopedic and spine care operations.
- Value
- $104M
- Counterparty
- multi-location musculoskeletal healthcare platform